2,694 reports of this reaction
1.3% of all OLANZAPINE reports
#17 most reported adverse reaction
AGITATION is the #17 most commonly reported adverse reaction for OLANZAPINE, manufactured by Eli Lilly and Company. There are 2,694 FDA adverse event reports linking OLANZAPINE to AGITATION. This represents approximately 1.3% of all 204,278 adverse event reports for this drug.
OLANZAPINE has an overall safety score of 88 out of 100. Patients taking OLANZAPINE who experience agitation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGITATION is a less commonly reported adverse event for OLANZAPINE, but still significant enough to appear in the safety profile.
In addition to agitation, the following adverse reactions have been reported for OLANZAPINE:
The following drugs have also been linked to agitation in FDA adverse event reports:
AGITATION has been reported as an adverse event in 2,694 FDA reports for OLANZAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGITATION accounts for approximately 1.3% of all adverse event reports for OLANZAPINE, making it a notable side effect.
If you experience agitation while taking OLANZAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.